Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» RNAi
RNAi
Novartis’s big wager on RNAi approaches the finish line
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Flag link:
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Flag link:
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Flag link:
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Alnylam
clinical trials
lumasiran
RNAi
PH1
Flag link:
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
Flag link:
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
Flag link:
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Fierce Biotech
JNJ
RNAi
JNJ-3989
hepatitis B
Flag link:
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Flag link:
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Regeneron
inclisiran
RNAi
Novartis
New England Journal of Medicine
Flag link:
Bayer helps Harvard spinout Vesigen to $28.5M series A
Bayer helps Harvard spinout Vesigen to $28.5M series A
Fierce Biotech
Bayer
Vesigen Therapeutics
Harvard
RNAi
MRNA
CRISPR
Flag link:
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Fierce Pharma
Alnylam
RNAi
Givlaari
acute hepatic porphyria
Flag link:
Dicerna nabs speedy review voucher for leading RNAi drug
Dicerna nabs speedy review voucher for leading RNAi drug
Fierce Biotech
Dicerna
RNAi
priority review
nedosiran
Flag link:
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Alnylam
clinical trials
RNAi
lumasiran
PH1
Flag link:
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Flag link:
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Flag link:
Alnylam's vutrisiran gets fast-track treatment at the FDA
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track
Flag link:
Blackstone backs Alnylam with up to $2B investment
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
generics
Alnylam
Blackstone
RNAi
Flag link:
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis
Pharmaceutical Business Review
Arrowhead Pharmaceuticals
clinical trials
cystic fibrosis
ARO-ENaC
RNAi
Flag link:
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Flag link:
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Flag link:
Pages
1
2
3
4
5
next ›
last »